In this intranasal route for treatment of CNS disorders, Gly14-humanin has been loaded, as a model neuropeptide drug, in cubosomes and evaluated for its pharmacodynamics in Alzheimer’s disease (AD) in rats. This evidence concerns the gene MT-RNR2 and Alzheimer disease.